Literature DB >> 20451614

The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands.

Antje Neubert1, Katia Verhamme, Macey L Murray, Gino Picelli, Yingfen Hsia, Fatma E Sen, Carlo Giaquinto, Adriana Ceci, M Sturkenboom, Ian C K Wong.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly prescribed drugs which are frequently used for the treatment of various painful conditions. However, particularly for the paediatric population, there is a lack of information on effectiveness, safety and appropriate formulation resulting in off-label use and undertreatment. The aim of this study was to investigate the prescribing patterns of non-steroid anti-inflammatory drugs and opioids in children and adolescents in three European countries. A retrospective cohort study was conducted using the same protocol in three primary care databases: Pedianet (Italy), IPCI (Netherlands) and IMS Disease Analyzer (UK). User prevalence rates were calculated for opioids (N02A) and non-steroidal anti-inflammatory drugs (NSAIDs) (M01A) based on ATC therapeutic and chemical levels and stratified by country, age and gender. The prescribing prevalence for NSAIDs was lower in the Netherlands compared to Italy and the UK. Ibuprofen was the most frequently prescribed drug in this group in Italy (20.8 users/1000 PY) and the UK (30.6 users/1000 PY) whereas diclofenac was dominant in the Netherlands (1.7 users/1000 PY). Among opioids, codeine and codeine combinations were most commonly prescribed; only little use was seen for other drugs. There is a great variety of different NSAIDs and opioids prescribed to children in Europe in primary care. This is due to a varying availability of drugs in different countries but also because of differing prescribing attitudes, reimbursement scheme and a lack of data on the effectiveness of individual drugs. Further research into the rationale for prescribing these drugs to children is clearly needed. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451614     DOI: 10.1016/j.phrs.2010.04.006

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  17 in total

1.  Epidemiology and potential associated risk factors of drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia.

Authors:  Asia N Rashed; Antje Neubert; Stephen Tomlin; John Jackman; Hani Alhamdan; Adnan AlShaikh; Ahmed Attar; Mohammed Aseeri; Lynda Wilton; Ian C K Wong
Journal:  Eur J Clin Pharmacol       Date:  2012-05-30       Impact factor: 2.953

2.  National patterns of codeine prescriptions for children in the emergency department.

Authors:  Sunitha V Kaiser; Renee Asteria-Penaloza; Eric Vittinghoff; Glenn Rosenbluth; Michael D Cabana; Naomi S Bardach
Journal:  Pediatrics       Date:  2014-04-21       Impact factor: 7.124

Review 3.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

4.  Adverse Drug Reactions in Children--International Surveillance and Evaluation (ADVISE): a multicentre cohort study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Barbara Hefele; Stephen Tomlin; John Jackman; Kenneth Lee; Kam-Lun E Hon; Jeffrey Ong; Maisoon Ghaleb; Siew Siang Chua; Tea Ming Hui; Wolfgang Rascher; Antje Neubert
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

5.  A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.

Authors:  Clara Sciorati; Daniela Miglietta; Roberta Buono; Viviana Pisa; Dario Cattaneo; Emanuele Azzoni; Silvia Brunelli; Emilio Clementi
Journal:  Pharmacol Res       Date:  2011-05-12       Impact factor: 7.658

6.  Analgesic Drug Prescription Patterns on Five International Paediatric Wards.

Authors:  Sebastian Botzenhardt; Asia N Rashed; Ian C K Wong; Stephen Tomlin; Antje Neubert
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

7.  Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries.

Authors:  Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Carlo Giaquinto; Gino Picelli; Alessandro Oteri; Sandra de Bie; Vera E Valkhoff; Martijn J Schuemie; Giampiero Mazzaglia; Claudio Cricelli; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

8.  Unlicensed use of metformin in children and adolescents in the UK.

Authors:  Yingfen Hsia; Dalia Dawoud; Alastair G Sutcliffe; Russell M Viner; Sanjay Kinra; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

9.  Adverse drug reactions in hospitalised children in Germany are decreasing: results of a nine year cohort-based comparison.

Authors:  Ann-Kathrin Oehme; Asia N Rashed; Barbara Hefele; Ian C K Wong; Wolfgang Rascher; Antje Neubert
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  An inventory of European data sources for the long-term safety evaluation of methylphenidate.

Authors:  Macey L Murray; Suppachai Insuk; Tobias Banaschewski; Antje C Neubert; Suzanne McCarthy; Jan K Buitelaar; David Coghill; Ralf W Dittmann; Kerstin Konrad; Pietro Panei; Eric Rosenthal; Edmund J Sonuga-Barke; Ian C K Wong
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-19       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.